Skip to main content
HALO logo
HALO
(NASDAQ)
Halozyme Therapeutics, Inc.
$80.84-- (--)
Loading... - Market loading

Halozyme Therapeutics (HALO) Stock Price & Financial Analysis

Halozyme Therapeutics Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$76.82 - $81.19
52-Week High$82.26
52-Week Low$57.68
Open$77.43
Volume1.72M
Average Volume (3M)1.83M
Market Cap9.93B
Shares Outstanding122.88M
P/E Ratio (TTM)28.47
Forward P/E39.26
Price to Sales (P/S)6.59
Price to Book (P/B)45.23
EV/EBITDA19.03
Revenue (TTM)1.51B
Net Income (TTM)348.84M
Free Cash Flow (TTM)667.65M
EPS (TTM)$2.87
Profit Margin23.13%
Operating Margin56.96%
Return on Equity (ROE)158.83%
Debt to Equity9.76
50-Day MA$72.66
200-Day MA$69.34
52-Week Change38.05%
Annual Dividend$0.00
Dividend Yield0.00%
Payout Ratio0.00%

Frequently Asked Questions About Halozyme Therapeutics

What is the current stock price for HALO?

As of the latest trading session, HALO stock trades at $80.84. The 52-week range is $57.68–$82.26, with a day range of $76.82–$81.19.

What is the P/E ratio for HALO?

Halozyme Therapeutics's trailing P/E ratio is 28.5, meaning investors pay $28.5 for every $1 of annual earnings. The forward P/E is 39.3, reflecting analyst expectations for future earnings. Halozyme Therapeutics operates in the Healthcare sector.

Does HALO pay dividends?

Halozyme Therapeutics does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.

What do analysts recommend for HALO?

Based on 8 analysts, the consensus for HALO is Buy.

What is the market cap of HALO?

Halozyme Therapeutics's market capitalization is $9.93B, classifying it as a mid-cap company. Halozyme Therapeutics operates in the Healthcare sector within the Biotechnology industry.